Reported about 16 hours ago
Sanofi plans to initiate a share buyback of 5 billion euros and signals potential for increased acquisitions following the anticipated sale of its controlling stake in the consumer health unit, Opella. This transition aims to focus solely on pharmaceuticals and vaccines, bolstered by a solid financial position. Despite a slight decline in quarterly operating income, sales for certain products like Beyfortus have seen significant growth.
Source: YAHOO